Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma
| Autor: | James H. Doroshow, Mario Sznol, Geoffrey R. Weiss, Paul Demchak, Michael J. Hawkins, Frederick R. Aronson, David H. Boldt, Geralyn Caliendo, Kathleen M. Grima, M H Bar, James W. Mier, Ellen R. Gaynor, Richard I. Fisher, Kim Margolin |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Cancer Research Pathology medicine.medical_specialty Continuous infusion Priming (immunology) chemical and pharmacologic phenomena Pharmacology law.invention Renal cell carcinoma law medicine Humans Neoplasm Metastasis Killer Cells Lymphokine-Activated Carcinoma Renal Cell Melanoma Aged Kidney Lymphokine-activated killer cell business.industry hemic and immune systems Middle Aged medicine.disease Combined Modality Therapy Kidney Neoplasms Recombinant Proteins medicine.anatomical_structure Oncology Evaluation Studies as Topic Toxicity Recombinant DNA Interleukin-2 Female business |
| Zdroj: | JNCI Journal of the National Cancer Institute. 82:1397-1402 |
| ISSN: | 1460-2105 0027-8874 |
| DOI: | 10.1093/jnci/82.17.1397 |
| Popis: | The current study was undertaken to determine the maximum tolerated dose of recombinant interleukin-2 (rIL-2) that could be administered as a continuous infusion in conjunction with autologous lymphokine-activated killer (LAK) cells. All 55 patients in this study received a priming dose of rIL-2 of 1.0 mg/m2 per day given as a continuous infusion over 4.5 days. Patients later received (days 11-16) one of three doses of rIL-2 per day (1.0, 1.25, or 1.50 mg/m2) in conjunction with LAK cells given on days 11, 12, and 14. Because of unacceptable toxicity occurring early in the LAK cell phase of therapy at the rIL-2 dose level of 1.50 mg/m2, we concluded that the maximum tolerated dose of rIL-2 given as a continuous infusion with LAK cells is 1.25 mg/m2 per day. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|